drugset / Trial / NCT02354612

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

NCT02354612

Expanded access No longer available Tracon Pharmaceuticals Inc.

Summary

Open-label, continuation study

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Carotuximab Monoclonal antibody
Background Axitinib Small molecule
Background Bevacizumab Monoclonal antibody
Background Capecitabine Small molecule
Background Pazopanib Small molecule

Indications